Literature DB >> 18071577

Synthesis and cyclometalation of a pyrido[3,2-e]-2,10b-diaza-cyclopenta[c]fluorene-1,3-dione scaffold.

Seann P Mulcahy1, Patrick J Carroll, Eric Meggers.   

Abstract

The synthesis of a pyrido[3,2-e]-2,10b-diaza-cyclopenta[c]fluorene-1,3-dione scaffold is disclosed, which was synthesized using a Suzuki cross-coupling reaction and an intramolecular Heck cyclization as the key steps. This heterocyclic system can serve as a bidentate ligand as demonstrated by the formation and structural analysis of a derived ruthenium complex. The new scaffold constitutes an interesting candidate for the development of organometallic protein kinase inhibitors.

Entities:  

Year:  2006        PMID: 18071577      PMCID: PMC2031847          DOI: 10.1016/j.tetlet.2006.10.054

Source DB:  PubMed          Journal:  Tetrahedron Lett        ISSN: 0040-4039            Impact factor:   2.415


  19 in total

1.  Rapid access to unexplored chemical space by ligand scanning around a ruthenium center: discovery of potent and selective protein kinase inhibitors.

Authors:  Howard Bregman; Patrick J Carroll; Eric Meggers
Journal:  J Am Chem Soc       Date:  2006-01-25       Impact factor: 15.419

Review 2.  Staurosporine, K-252 and UCN-01: potent but nonspecific inhibitors of protein kinases.

Authors:  U T Rüegg; G M Burgess
Journal:  Trends Pharmacol Sci       Date:  1989-06       Impact factor: 14.819

3.  Organometallic compounds with biological activity: a very selective and highly potent cellular inhibitor for glycogen synthase kinase 3.

Authors:  G Ekin Atilla-Gokcumen; Douglas S Williams; Howard Bregman; Nicholas Pagano; Eric Meggers
Journal:  Chembiochem       Date:  2006-09       Impact factor: 3.164

4.  An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage.

Authors:  J R Jackson; A Gilmartin; C Imburgia; J D Winkler; L A Marshall; A Roshak
Journal:  Cancer Res       Date:  2000-02-01       Impact factor: 12.701

Review 5.  Metal-based antitumour drugs in the post genomic era.

Authors:  Paul J Dyson; Gianni Sava
Journal:  Dalton Trans       Date:  2006-03-28       Impact factor: 4.390

6.  Palladium-catalyzed cross-coupling reactions of pyridylboronic acids with heteroaryl halides bearing a primary amine group: synthesis of highly substituted bipyridines and pyrazinopyridines.

Authors:  Amy E Thompson; Gregory Hughes; Andrei S Batsanov; Martin R Bryce; Paul R Parry; Brian Tarbit
Journal:  J Org Chem       Date:  2005-01-07       Impact factor: 4.354

7.  Synthesis and biological evaluation of novel naphthocarbazoles as potential anticancer agents.

Authors:  Sylvain Routier; Paul Peixoto; Jean-Yves Mérour; Gérard Coudert; Nathalie Dias; Christian Bailly; Alain Pierré; Stéphane Léonce; Daniel-Henry Caignard
Journal:  J Med Chem       Date:  2005-03-10       Impact factor: 7.446

8.  Selective inhibition of protein kinase C isozymes by the indolocarbazole Gö 6976.

Authors:  G Martiny-Baron; M G Kazanietz; H Mischak; P M Blumberg; G Kochs; H Hug; D Marmé; C Schächtele
Journal:  J Biol Chem       Date:  1993-05-05       Impact factor: 5.157

9.  Ruthenium complexes as protein kinase inhibitors.

Authors:  Lilu Zhang; Patrick Carroll; Eric Meggers
Journal:  Org Lett       Date:  2004-02-19       Impact factor: 6.005

10.  Synthesis of 6H-pyrrolo[3',4':2,3][1,4]diazepino[6,7,1-hi]indole-8,10(7H,9H)-diones using 3-bromo-4-(indol-1-yl)maleimide scaffold.

Authors:  Sergey A Lakatosh; Yuri N Luzikov; Maria N Preobrazhenskaya
Journal:  Org Biomol Chem       Date:  2003-03-07       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.